Premium
Safety and efficacy of single‐agent ibrutinib in patients with relapsed/refractory ( R/R ) marginal zone lymphoma ( MZL ): A multicenter, open‐label, phase 2 study
Author(s) -
Collins G.P.,
Noy A.,
Vos S.,
Thieblemont C.,
Martin P.,
Flowers C.,
Morschhauser F.,
Ma S.,
Coleman M.,
Peles S.,
Smith S.,
Barrientos J.,
Smith A.,
Munneke B.,
Dimery I.,
Beaupre D.,
Chen R.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_76
Subject(s) - medicine , ibrutinib , rituximab , chemoimmunotherapy , regimen , progression free survival , gastroenterology , phases of clinical research , oncology , lymphoma , chronic lymphocytic leukemia , chemotherapy , leukemia